Investigating how chemotherapy affects ovarian function and fertility in young women
Oogenic JNK in gonadotoxic chemotherapy-induced primary ovarian insufficiency
This study is looking at how common chemotherapy drugs can affect the ovaries and fertility in young women who have survived cancer, with the hope of finding ways to protect their reproductive health during treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers Biomedical and Health Sciences NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project ID | NIH-11170518 on NIH RePORTER |
What this research studies
This research focuses on understanding the impact of common chemotherapy drugs on ovarian function, specifically how they can lead to primary ovarian insufficiency (POI) and infertility in young female cancer survivors. The study examines the mechanisms by which these drugs cause damage to the oocytes in primordial follicles, which are crucial for female fertility. By using genetically modified mouse models, the researchers aim to identify specific signaling pathways involved in this process, potentially leading to new strategies to protect ovarian function during cancer treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are young female cancer patients who are at risk of developing ovarian insufficiency due to chemotherapy.
Not a fit: Patients who are not undergoing chemotherapy or who are not female may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved fertility preservation strategies for young women undergoing chemotherapy.
How similar studies have performed: Previous research has shown that understanding the mechanisms of chemotherapy-induced ovarian damage can lead to protective strategies, indicating that this approach has potential for success.
Where this research is happening
Newark, UNITED STATES
- Rutgers Biomedical and Health Sciences — Newark, United States (Active)
Researchers
- Principal investigator: Xiao, Shuo — Rutgers Biomedical and Health Sciences
- Study coordinator: Xiao, Shuo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.